Mauricio Lema Medina MD

www.mauriciolema.com
CRC
NOMBRE PACIENTE (IDENTIFICACIÓN)
Esquema: FOLFOXIRI
Descripción Folinato, fluoruracilo infusional, Irinotecán y oxaliplatino
Referencia Falcone, A. et al. J Clin Oncol 2007 25: 1670-1676
Indicación Cáncer colon y recto

Presentaciones
Medicamento Presentación Cantidad Unidades
Folinato de calcio Amp 50 mg
Fluoruracilo Amp 500 mg
Irinotecán Amp 100 mg
Oxaliplatino Amp 50 mg

Talla (cm) 160 Entrar la talla

Peso (kg) 56 Entrar el peso
Superficie corporal (m2) 1.58 El programa calcula la superficie corporal
Intensidad de dosis (%) 100 Entrar la intensidad de dosis

Cálculo de dosis
Medicamento mg/m2 Dosis 100% Dosis Calculada No. Ampollas Amp/inf Amp/ciclo
Folinato de calcio 200 315 315 6.31 7 14
Fluoruracilo 3200 5047 5047 10.09 11 22
Irinotecán 165 260 260 2.60 3 6
Oxaliplatino 85 134 134 2.68 3 6

Solicitud de Medicamentos

Medicamento Presentación Cantidad Unidades Número

Folinato de calcio Amp 50 mg 14
Fluoruracilo Amp 500 mg 22
Irinotecán Amp 100 mg 6
Oxaliplatino Amp 50 mg 6
Dexametasona Amp 4 mg 10
Ondansetrón Amp 8 mg 2

Protocolo de administración en la página 2

 Mauricio Lema Medina MD
www.mauriciolema.com
CRC

Página 2
Protocolo de Administración
Premedicación Dosis Unidades Descripción
Ondansetron 8 mg IV antes de quimioterapia día 1 y 2
Dexametasona 20 mg IV antes de quimioterapia día 1 y 2
Posteriormente
Irinotecán 260 mg en D5% 500 IV en 60 minutos, día 1
Oxaliplatino 134 mg en D5% 500 IV en 120 minutos, día 1
Folinato de calcio 315 mg IV en SSN 250 cc, infusión de 120 minutos, día 1
Fluoruracilo 5047 mg En infusión intravenosa continua de 48 horas,
iniciando en el día 1
Repetir el anterior protocolo en el día 15
Bases:
Irinotecán 165 mg/m2 en 60 minutos, Folinato 200 mg/m2 infusión 2 horas, Fluoruracilo 3200 mg/m2 en infusió 48 horas
Oxaliplatino 85 mg/m2, en infusión de 2 horas, día 1; se repite cada 15 días
BSA fórmula: 0,20274*POTENCIA(C13/100;0,725)*POTENCIA(C14;0,425)

Hoja Creada por: Mauricio Lema Medina MD

Falcone, Alfredo, Ricci, Sergio, Brunetti, Isa, Pfanner, Elisabetta, Allegrini, Giacomo, Barbara, Cecilia, Crino, Lucio, Benedetti, Giovanni, Evange
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluoro
J Clin Oncol 2007 25: 1670-1676

From November 2001 to April 2005, we enrolled patients who met the following eligibility criteria: adenocarcinoma of the co
 , Benedetti, Giovanni, Evangelista, Walter, Fanchini, Laura, Cortesi, Enrico, Picone, Vincenzo, Vitello, Stefano, Chiara, Silvana, Granetto, Cristina, Porcile, Gia
ared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo

adenocarcinoma of the colon or rectum, unresectable metastatic disease, age 18 to 75 years, Eastern Cooperative Oncology Group (EC
Granetto, Cristina, Porcile, Gianfranco, Fioretto, Luisa, Orlandini, Cinzia, Andreuccetti, Michele, Masi, Gianluca
rectal Cancer: The Gruppo Oncologico Nord Ovest

ative Oncology Group (ECOG) performance status of 2 or lower if age 70 years or younger or ECOG performance status of 0 if age 71
ance status of 0 if age 71 to 75 years, measurable disease according to WHO criteria, leukocyte count of at least 3,500/mm
ast 3,500/mm 3, neutrophils count of at least 1,500/mm 3, platelet count of at least 100,000/mm 3, serum creatinine of 1.3 mg/dL or less, se
ne of 1.3 mg/dL or less, serum bilirubin less than 1.5 mg/dL and AST, ALT, and alkaline phosphatase 2.5 x normal values or less ( 5 if li
rmal values or less ( 5 if liver metastases). Previous fluoropyrimidine-based adjuvant chemotherapy was allowed if ended more than 6 m
ed if ended more than 6 months before random assignment. Exclusion criteria were previous palliative chemotherapy for metastatic dise
herapy for metastatic disease; previous chemotherapy including irinotecan or oxaliplatin, symptomatic cardiac disease, myocardial
disease, myocardial infarction in the last 24 months or uncontrolled arrhythmia, active infections, inflammatory bowel disease; and total
y bowel disease; and total colectomy. The study was conducted in accordance to Helsinki declaration and to Good Clinical Practice guid
Good Clinical Practice guidelines, and patients were informed of the investigational nature of the study and provided their written informe
vided their written informed consent before registration onto the study. The protocol was approved by the ethics committee of
cs committee of all participating institutions.